Last reviewed · How we verify
OnaBoNT-A
At a glance
| Generic name | OnaBoNT-A |
|---|---|
| Also known as | Botox®, Botox, onabotulinumtoxinA, BOTOX(R) |
| Sponsor | Ipsen |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficiency of Botulinum Toxin type-a in the Management of the Myofascial Pain (NA)
- A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity. (PHASE4)
- Intraoral Administration of Botox in Patients With Dentoalveolar Neuropathic Pain (PHASE2)
- A Study Comparing the Safety, Efficacy, and Diffusion of Letibotulinum Toxin A Versus Other Botulinum Toxin Products in Adults With Moderate-to-Severe Forehead Wrinkles (PHASE4)
- Comparing Treatments for Refractory Overactive Bladder: Bladder Denervation vs Botulinum Toxin Injections (PHASE4)
- A Pilot Study Testing Onabotulinum Toxin A Versus Incobotulinum Toxin A Injections for Facial Wrinkles (EARLY_PHASE1)
- Effect of Intradetrusor onabotulinumtoxinA Injection Versus Conservative Management on Female Sexual Function in Patients With Bladder Pain Syndrome
- Optimal Intravesical Lidocaine Volume for Pain Relief During Office Intra-detrusor Onabotulinum Toxin a Injections (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OnaBoNT-A CI brief — competitive landscape report
- OnaBoNT-A updates RSS · CI watch RSS
- Ipsen portfolio CI